Sapna Syngal, MD, MPH
A new study has documented a nine-fold higher risk of pancreatic cancer in individuals with Lynch syndrome, a rare genetic cancer predisposition syndrome, report scientists from the Dana-Farber Cancer Institute and the University of Michigan.
The study, published in the Oct. 28 issue of the Journal of the American Medical Association, is the first using rigorous statistical methods to confirm the elevated risk, the authors say. Previous studies yielded conflicting results.
"In light of these findings, we believe that if you have Lynch syndrome and there is pancreatic cancer in your family, you should be closely monitored," said Sapna Syngal, MD, MPH, of Dana-Farber and Brigham and Women's Hospital.
Carriers of the Lynch syndrome gene mutations have an 80 percent risk of colorectal cancer beginning at a young age, as well as an array of other cancers of the digestive system, brain and skin, and endometrium and ovaries in women.
Syngal, director of gastroenterology at Dana-Farber/Brigham and Women's Cancer Center, is the report's senior author along with Stephen B. Gruber, MD, PhD, MPH, associate director for cancer prevention and control at the University of Michigan Comprehensive
Fay Kastrinos, MD, MPH, first author of the publication, noted, "Patients with Lynch syndrome are living longer because we're doing a better job with colonoscopic screening and using genetic testing as a strategy for the prevention of colon cancer."
In light of the new findings, she said, "Lynch syndrome families with pancreatic cancer should be included in ongoing studies to test the effectiveness of screening modalities for pancreatic cancer."
Kastrinos's research was carried out while at Brigham and Women's Hospital; she is currently at the Herbert Irving Comprehensive Cancer Center at New York City's Columbia University Medical Center and directs the hereditary colorectal cancer center.
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, according to the American Cancer Society, which projects 42,470 cases diagnosed
in 2009, and 35,240 deaths.
While colorectal cancer is increasingly being detected early and prevented through colonoscopies and removal of precancerous polyps, there is currently no effective means of early diagnosis for pancreatic cancer.
Scientists are testing imaging techniques such as endoscopic ultrasound, CT and MRI scanning in an effort to detect small, treatable tumors, but to date there is no evidence of a survival benefit. Investigators are also searching for biomarkers that might
signal the early stages of the disease.
Mutations in several "mismatch repair" genes that fix copying errors in DNA underlie Lynch syndrome. The researchers designed the study to estimate the risk of pancreatic cancer in families with these inherited mutations. A total of 147 families were
drawn from colorectal cancer registries at Dana-Farber and the University of Michigan Comprehensive Cancer Center.
"Because pancreatic cancer is a relatively rare cancer, pooling together the databases at the University of Michigan and Dana-Farber was critical to this analysis," commented first co-author Bhramar Mukherjee, PhD, a biostatistician at the University
of Michigan School of Public Health.
"Genetic counseling clinics tend to see more patients from families with multiple cancers, which means risk estimates obtained by a naïve statistical method are often highly inflated," said Mukherjee. "We used appropriate methods to adjust for this bias
to provide families with more realistic risk estimates of pancreatic cancer."
The analysis revealed a nine-fold increase in risk of the disease compared with the general population, and the cancer tended to appear earlier. The absolute risk of pancreatic cancer in the Lynch families was 1.31 percent at age 50 and 3.68 percent at
70 years. In the general population, there is only a 0.04 percent risk at 50 years and a 0.52 percent risk at age 70.
Syngal, who is also an associate professor of medicine at Harvard Medical School, noted that pancreatic cancers appear to "cluster" in some Lynch syndrome families, while others don't have an increased incidence of the disease. For that reason, she said,
screening is recommended only for patients carrying the Lynch mutations who also have a family history of pancreatic cancer.
The research was funded by the National Cancer Institute and private supporters. The study's other authors are Nabihah Tayob, MS, Victoria M. Raymond, MS, and Fei Wang, MS, University of Michigan School of Public Health, Ann Arbor; and Jennifer Sparr,
MD, Prathap Bandipalliam, MD, Elena M. Stoffel, MD, MPH, Dana-Farber.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard
Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent
hospitals of National Cancer Institute and National Institutes of Health grant funding.
The mission of the U-M Comprehensive Cancer Center is the conquest of cancer through innovation and collaboration. One of 41 centers to receive the National Cancer Institute's "comprehensive" designation, the center provides its patients diagnostic, treatment,
and support services in a collaborative environment, focused on excellence in patient care. Drawing on the strengths of the University of Michigan faculty, the Cancer Center has assembled a team of specialists who are leaders in their fields to unravel
the threat of cancer and to provide care and comfort to those it affects. For information, visit www.mcancer.org.